The shingles vaccine appears to offer additional benefits
Cavan images / Aramie
Vaccination against herpes zoster, well known as shingles, does not only help prevent this painful infection. It also reduces the risk of cardiovascular problems.
A new observational study of over 1 million people shows that those who receive a single injection of the shingles vaccine Zostavax are 26% less likely to experience heart disease, heart attack, or heart failure compared to those who have not received the vaccine.
“I know that shingles causes inflammation of the blood vessels,” she says. “So, by preventing infection, vaccines may reduce the risk of cardiovascular disease.”
Shingles occurs when the water cell zoster virus, which causes chicken and then stays in the body after symptoms clear, is reactivated. This can occur when the immune system is weakened, such as stress or duration of chemotherapy. Shingles causes painful rashes.
Cardiovascular events are like that Usually not listed as a complication Scientists know about shingles now Shingles is linked Especially within the first year of an infection, the risk of stroke increases by about 30% and the risk of heart attack increases by 10%.
To see if vaccinations alleviated this issue, Lee and her colleagues collected data from 1,271,922 people over the age of 50, collected by the South Korean National Health Registry Bureau between 2012 and 2024. The researchers determined whether each person received a live iron vaccine and compared it to the late development of any of 18 cardiovascular diseases, including heart failure, stroke, thrombosis, arrhythmia, and ischemia. The team also investigated other health-related factors, such as age, gender, socioeconomic status, exercise level, and social habits.
Over the six-year average follow-up period, Lee says the risk of post-vaccination cardiovascular events was 23% lower than that of people who were not vaccinated.
Risk was further reduced in men – vaccinations associated with a 27% lower risk compared to a 20% decline in women resulted in a 27% lower risk even in people under 60 years of age, compared to 16% of older people. Rural residents fell 25% compared to 20% of urban people, while low-income individuals showed a 26% decline, while higher earners showed a 20% decline. For obese people, the risk reduction decreased as BMI increased.
For certain cardiovascular events, vaccinated individuals were 26% less likely to suffer a stroke, heart attack, or heart failure, and also 26% less likely to die from heart disease. Meanwhile, the risk of coronary artery disease was reduced by 22%.
Profits were most prominent two to three years after vaccination, then gradually fell over the next five years.
The study states that shingles vaccination “strengthens our confidence” that it reduces cardiovascular risk by reducing vascular inflammation, possibly caused by the shingles virus. Gallen Faulke At Pennsylvania State University.
“Ships zoster itself is a high incidence of pain and neuralgia after herpes, which is a painful condition that follows the eruption,” he says. “However, health systems around the world have been able to find significant medical treatment by reducing cardiovascular morbidity by investing in relatively inexpensive shingles vaccines.”
More research is needed, but scientists suspect that the vaccine will help indirectly reduce cardiovascular risks to prevent shingles.
Researchers first focused on Singlix (viral proteins, not the virus itself, as Zostavax is available for longer periods of time). Now they’re paying attention to Singrix.
“That’s why It is more effective in preventing shinglesI think recombinant vaccines could provide even stronger cardiovascular protection,” says Lee.
Although the study design does not prove the cause and effectiveness as in randomized trials, researchers can identify risk associations for large numbers of people. Such large data could reveal risk patterns that clinical trials may miss, explains Lee.
topic:
